Novel ruthenium complexes as potential drugs for Chagas's disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity

British Journal of Pharmacology

Volumn 160, Issue 2, 2010, Pages 260-269

  Silva, Jean Jerley Nogueira ^a   Guedes, Paulo Marcos Matta ^a   Zottis, Aderson ^a   Balliano, Tatiane Luciano ^a   Nascimento Silva, Francisco Ordelei ^b   França Lopes, Luiz Gonzaga ^b   Ellena, Javier ^a   Oliva, Glaucius ^a   Andricopulo, Adriano Defini ^a   Franco, Douglas Wagner ^a   Silva, João Santana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

GAPDH; Medicinal inorganic chemistry; NO donors; Ruthenium; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; CYSTEINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE DONOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RUTHENIUM COMPLEX;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ERADICATION THERAPY; FEMALE; HEART MUSCLE; HISTOPATHOLOGY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; TRYPANOSOMA CRUZI; X RAY DIFFRACTION;

ANIMALS; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; NITRIC OXIDE; NITRIC OXIDE DONORS; RUTHENIUM COMPOUNDS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 77951670397     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00524.x     Document Type: Article

References (41)

1. Blessing RH (1995). An empirical correction for absorption anisotropy. Acta Crystallogr A A51 : 33 38.
2. Borges SSS, Davanzo CU, Castellano EE, Z-Zchpector J, Silva SC, Franco DW (1998). Ruthenium nitrosyl complexes with N-heterocyclic ligands. Inorg Chem 37 : 2670 2677.
3. Bourguignon SC, Alves CR, Giovanni-De-Simone S (1997). Detrimental effect of nitric oxide on Trypanosoma cruzi and Leishmania major like cells. Acta Trop 66 : 109 118. (Pubitemid 27285950)
4. Brener Z (1962). Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 4 : 389 396.
5. Bruce RD (1985). An up-and-down procedure for acute toxicity testing. Fundam Appl Toxicol 5 : 151 157.
6. Castro JA, Meca MM, Bartel LC (2006). Toxic side effect of drugs used to treat Chagas's disease (American trypanosomiasis). Hum Exp Toxicol 25 : 471 479.
7. + complexes. Eur J Inorg Chem 2006 : 2020 2026.
8. Engels D, Savioli L (2006). Reconsidering the underestimated burden caused by neglected tropical diseases. Trends Parasitol 22 : 363 366. (Pubitemid 44108758)
9. Enraf-Nonius (1997). COLLECT. Nonius BV
10. Farrugia LJJ (1997). ORTEP3 for Windows. J Appl Crystallogr 30 : 565.
11. Farrugia LJJ (1999). WinGX. WinGX suite for small-molecule single-crystal crystallogrraphy. J Appl Crystallogr 32 : 837 838.
12. Guedes PMM, Veloso VM, Caliari MV, Carneiro CM, Souza SM, de Lana M et al. (2007). Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in Beagle dogs. Mem Inst Oswaldo Cruz 102 : 141 147. (Pubitemid 46535873)
13. Guido RVC, Oliva G, Montanari CA, Andricopulo AD (2008). Structural basis for selective inhibition of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase: molecular docking and 3D QSAR studies. J Chem Inf Model 48 : 918 929. (Pubitemid 351757757)
14. Gutierrez FRS, Mariano FS, Miranda-Santos IKF, Silva JS (2007). Effector mechanisms of macrophages infected with Trypanosoma cruzi. In : Denkers EY, Gazzinelli RT (eds). Protozoans in Macrophages, 1st edn. Medical Intelligence Unit, Landes Bioscience
15. Hamaguchi T, Inoue Y, Ujimoto K, Ando I (2008). Synthesis, crystal structure and electrochemistry of a ruthenium complex coordinated with an ambidentate 2-mercaptopyridinato N-oxide ligand. Polyhedron 27 : 2031 2034.
16. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS (2005). Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6 : 150 166. (Pubitemid 40215810)
17. Lopez BE, Wink DA, Fukuto JM (2007). The inhibition of glyceraldehyde-3-phosphate dehydrogenase by nitroxyl (HNO). Arch Biochem Biophys 465 : 430 436.
18. Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faúdez M, Galanti N et al. (2007). Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146 : 601 620. (Pubitemid 46341910)
19. Mohr S, Stamler JS, Brüne B (1994). Mechanism of covalent modification of glyceraldehyde-3-phosphate dehydrogenase at its active site thiol by nitric oxide, peroxynitrite and related nitrosating agents. FEBS Lett 348 : 223 227. (Pubitemid 2114056)
20. Mohr S, Stamler JS, Brüne B (1996). Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. J Biol Chem 271 : 4209 4214. (Pubitemid 26070523)
21. Opperdoes FR (1985). Biochemical peculiarities of Trypanosoma african and south american. Br Med Bull 41 : 130 136.
22. Otwinowski Z, Minor W, Denzo HKL (1997). Scalepack. In : Carter CW Jr., Sweet RM (eds). Methods in Enzymology, Vol. 276. Academic Press
23. Pacher P, Beckman JS, Liaudet L (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 : 315 424. (Pubitemid 46217686)
24. Pereira JM, Severino RP, Vieira PC, Fernandes JB, da Silva MFGF, Zottis A et al. (2008). Anacardic acid derivatives as inhibitors of glyceraldehyde-3- phosphate dehydrogenase from Trypanosoma cruzi. Bioorg Med Chem 16 : 8889 8895.
25. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA (2007). Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA 298 : 1911 1924. (Pubitemid 350005235)
26. Roncaroli F, Olabe JA (2005). The reactions of nitrosyl complexes with cysteine. Inorg Chem 44 : 4719 4727. (Pubitemid 41024907)
27. Sachs JD (2007). The neglected tropical diseases. Sci Am 296 : 33A.
28. 50 test. Regul Toxicol Pharmacol 42 : 15 23. (Pubitemid 40724412)
29. Sheldrick GM (1997). SHELXS-97. Program for crystal structure resolution. Univ. of Göttingen: Göttingen, Germany.
30. Silva LHP, Nussenzweig V (1953). Sobre uma cepa altamente virulenta para o camundongo branco. Folia Clin Biol (Sao Paulo) 20 : 191 208.
31. Silva JS, Machado FS, Martins GA (2003). The role of nitric oxide in the pathogenesis of Chagas' disease. Front Biosci 1 : s314 s325.
32. Silva RSF, Costa EM, Trindade ULT, Teixeira DV, Pinto MCFR, Santos GL et al. (2006). Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi. Eur J Med Chem 41 : 526 530.
33. Silva JJN, Osakabe AL, Pavanelli WR, Silva JS, Franco DW (2007). In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br J Pharmacol 152 : 112 121.
34. Silva JJN, Pavanelli WR, Gutierrez FRS, Lima FCA, da Silva ABF, Silva JS et al. (2008). Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J Med Chem 51 : 4104 4114.
35. Silva JJN, Pavanelli WR, Pereira JCM, Silva JS, Franco DW (2009). Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob Agents Chemother 53 : 50 58.
36. Souza JM, Radi R (1998). Glyceraldehyde-3-phosphate dehydrogenase inactivation by peroxynitrite. Arch Biochem Biophys 360 : 187 194. (Pubitemid 29001747)
37. Souza DHF, Garratt RC, Araújo APU, Guimarães BG, Jesus WDP, Michels PAM et al. (1998). Trypanosoma cruzi glycosomal glyceraldehyde-3- phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. FEBS Lett 424 : 131 135.
38. Tfouni E, Krieger M, McGarvey B, Franco DW (2003). Structure, chemical and photochemical reactivity and biological activity of some ruthenium nitrosyl complexes. Coord Chem Rev 236 : 57 69.
39. Turrens JF (2004). Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. Mol Aspects Med 25 : 211 220.
40. Verline CLMJ, Hannaert V, Blonski C, Willson M, Périé JJ, Fathergill-Gilmore LA et al. (2001). Glycolysis as target for the design of new anti-trypanosome drugs. Drug Resist Updat 4 : 1 14. (Pubitemid 32267825)
41. World Health Organization (WHO) (2005). Tropical disease research: progress 2003-2004 seventeenth programme report of the UNICEF/UNDP/World Bank/WHO. In : Chan M, Heymann D, Ridley R (eds). Special Programme for Research & Training in Tropical Diseases (TDR). World Health OrganizationC